Literature DB >> 15911245

Photothermal sensitisation as a novel therapeutic approach for tumours: studies at the cellular and animal level.

Monica Camerin1, Santiago Rello, Angeles Villanueva, Xinzhan Ping, Malcolm E Kenney, Michael A J Rodgers, Giulio Jori.   

Abstract

Irradiation of B78H1 murine amelanotic melanoma cells with 850 nm light emitted from a Ti:sapphire laser, operated in a pulsed mode at high fluence rates and in the presence of Ni(II)-octabutoxy-naphthalocyanine (NiNc), promoted a photothermally sensitised process leading to fast and irreversible cell death. This resulted in the ejection of a consistent mass of cytoplasmic material from the irradiated cells that was detected by scanning electron microscopy. The extensive chemical and mechanical damage was probably caused by the photoinduced generation of an acoustic shock wave. The efficiency of the photoprocess was modulated by intracellular concentration of NiNc and maximally by the formation of aggregated naphthalocyanine clusters in specific subcellular areas. Very similar results were obtained upon irradiation of NiNc-loaded C32 human amelanotic melanoma cells and transformed murine HT-1080 and HaCaT fibroblasts. From these results, photothermal sensitisation appears to be a general phenomenon and preliminary studies with mice bearing subcutaneously transplanted amelanotic melanomas, irradiated with 850 nm light 24 h after intravenous injection of NiNc, suggest that this approach has potential for the therapy of some types of skin tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911245     DOI: 10.1016/j.ejca.2005.02.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

Review 1.  Plasmonic photothermal therapy (PPTT) using gold nanoparticles.

Authors:  Xiaohua Huang; Prashant K Jain; Ivan H El-Sayed; Mostafa A El-Sayed
Journal:  Lasers Med Sci       Date:  2007-08-03       Impact factor: 3.161

2.  Diagnostic and Therapeutic Nanomedicine.

Authors:  Jinmyoung Joo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  The Synthesis and Characterization of a Group of Transition Metal Octabutoxynaphthalocyanines and the Absorption and Emission Properties of the Co, Rh, Ir, Ni, Pd and Pt Members of This Group.

Authors:  Junhwan Kim; Alexandra V Soldatova; Michael A J Rodgers; Malcolm E Kenney
Journal:  Polyhedron       Date:  2013-07-02       Impact factor: 3.052

4.  Plasmonic nanoparticle-generated photothermal bubbles and their biomedical applications.

Authors:  Dmitri Lapotko
Journal:  Nanomedicine (Lond)       Date:  2009-10       Impact factor: 5.307

5.  Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres.

Authors:  Wei Lu; Chiyi Xiong; Guodong Zhang; Qian Huang; Rui Zhang; Jin Z Zhang; Chun Li
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 6.  Shedding light on nanomedicine.

Authors:  Rong Tong; Daniel S Kohane
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-08-09

Review 7.  MRI-guided monitoring of thermal dose and targeted drug delivery for cancer therapy.

Authors:  Ruchika Fernando; Jon Downs; Danny Maples; Ashish Ranjan
Journal:  Pharm Res       Date:  2013-06-19       Impact factor: 4.200

8.  Multi-dye theranostic nanoparticle platform for bioimaging and cancer therapy.

Authors:  Amit K Singh; Megan A Hahn; Luke G Gutwein; Michael C Rule; Jacquelyn A Knapik; Brij M Moudgil; Stephen R Grobmyer; Scott C Brown
Journal:  Int J Nanomedicine       Date:  2012-06-01

9.  Porphyrins as theranostic agents from prehistoric to modern times.

Authors:  Yumiao Zhang; Jonathan F Lovell
Journal:  Theranostics       Date:  2012-09-30       Impact factor: 11.556

10.  Ablation of hypoxic tumors with dose-equivalent photothermal, but not photodynamic, therapy using a nanostructured porphyrin assembly.

Authors:  Cheng S Jin; Jonathan F Lovell; Juan Chen; Gang Zheng
Journal:  ACS Nano       Date:  2013-02-12       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.